IDEXX Laboratories Company Profile (NASDAQ:IDXX)

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its Board of Directors has approved a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its earnings results on Tuesday, August, 1st. The company reported $0.95 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million for the quarter, compared to analyst estimates of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The business's quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.74 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories updated its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $3.12-3.22 for the period, compared to the Thomson Reuters consensus estimate of $3.07. The company issued revenue guidance of $1.945-1.965 billion, compared to the consensus revenue estimate of $1.94 billion.

6 brokers have issued 12 month target prices for IDEXX Laboratories' stock. Their predictions range from $118.00 to $200.00. On average, they expect IDEXX Laboratories' stock price to reach $171.60 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

• 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
• 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Some companies that are related to IDEXX Laboratories include Essilor International SA (ESLOY), Astellas Pharma (ALPMY), Incyte Corporation (INCY), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Zimmer Biomet Holdings (ZBH), C.R. Bard (BCR), Cardinal Health (CAH), Quintiles Transitional Holdings (Q), Lonza Group Ag (LZAGY), Teva Pharmaceutical Industries Limited (TEVA), AmerisourceBergen Corporation (Holding Co) (ABC), Mylan N.V. (MYL), Centene Corporation (CNC), BioMarin Pharmaceutical (BMRN), Smith & Nephew SNATS (SNN), Laboratory Corporation of America Holdings (LH) and Eisai Co., Ltd (ESALY).

IDEXX Laboratories' management team includes the folowing people:

• Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
• Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
• Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
• Jay Mazelsky, Executive Vice President
• Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
• William T. End, Lead Independent Director
• Bruce L. Claflin, Independent Director
• Stuart M. Essig Ph.D., Independent Director
• Rebecca M. Henderson Ph.D., Independent Director
• Daniel M. Junius, Independent Director

IDEXX Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.62%), BlackRock Inc. (8.14%), Bamco Inc. NY (5.42%), Fundsmith LLP (5.09%), State Street Corp (4.39%) and Blair William & Co. IL (2.04%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, JPMorgan Chase & Co., Fiera Capital Corp, Bamco Inc. NY, Neuberger Berman Group LLC, Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado and Prudential Financial Inc.. Company insiders that have sold IDEXX Laboratories stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDEXX Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Koch Industries Inc., Janus Henderson Group PLC, BlackRock Inc., Old Mutual Global Investors UK Ltd., Arrowstreet Capital Limited Partnership, Renaissance Technologies LLC, Goldman Sachs Group Inc. and Vanguard Group Inc.. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDEXX Laboratories stock can currently be purchased for approximately $162.10.